

Glenmark initiates myeloma drug trial

08 December 2017 | News

GBR 1342 is an investigational new drug from the company's immuno-oncology portfolio.



Glenmark Pharma has initiated the phase-1 clinical trial of GBR 1342, an investigational antibody for treatment of multiple myeloma.

GBR 1342 is an investigational new drug from the company's immuno-oncology portfolio.

Glenmark had received clearance from US health regulator in May this year, for the investigational new drug application to initiate phase-1 study of GBR 1342.

This first-in-human, open-label study's primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached.

The additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti- tumour activity.